CeNes Pharmaceuticals (U.S.) Starts Recruitment for Phase II trial of CNS 5161 for Cancer Pain

LONDON (Thomson Financial) - CeNeS Pharmaceuticals PLC said it has started recruitment for a Phase II study of the potential new pain drug CNS 5161, which is being developed under a co-development deal with the ERGOMED Group.